Citigroup Inc Standard Biotools Inc. Transaction History

Citigroup Inc

$163 Billion
Q4 2024

A detailed history of Citigroup Inc transactions in Standard Biotools Inc. stock. As of the latest transaction made, Citigroup Inc holds 247,855 shares of LAB stock, worth $282,554. This represents 0.0% of its overall portfolio holdings.

Number of Shares

247,855

Previous 230,625 7.47%

Holding current value

$282,554

Previous $445,000 2.7%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 12, 2025	BUY	$1.5 - $2.26 $25,845 - $38,939	17,230 Added 7.47%	247,855 $433,000
Q3 2024 Nov 12, 2024	BUY	$1.42 - $2.35 $219,661 - $363,523	154,691 Added 203.72%	230,625 $445,000
Q2 2024 Aug 12, 2024	SELL	$1.65 - $2.92 $990,399 - $1.75 Million	-600,242 Reduced 88.77%	75,934 $134,000
Q1 2024 May 10, 2024	BUY	$1.87 - $2.78 $659,369 - $980,239	352,604 Added 108.97%	676,176 $1.83 Million
Q4 2023 Feb 09, 2024	BUY	$1.59 - $2.73 $212,711 - $365,222	133,781 Added 70.49%	323,572 $715,000
Q3 2023 Nov 09, 2023	BUY	$1.9 - $3.05 $360,602 - $578,862	189,791 New	189,791 $550,000
Q4 2022 Feb 09, 2023	SELL	$0.93 - $1.52 $4 - $7	-5 Reduced 7.58%	61 $0
Q3 2022 Nov 10, 2022	SELL	$1.1 - $2.06 $1,896 - $3,551	-1,724 Reduced 96.31%	66 $0
Q2 2022 Aug 10, 2022	SELL	$1.6 - $3.99 $6,104 - $15,221	-3,815 Reduced 68.06%	1,790 $3,000
Q1 2022 May 12, 2022	SELL	$2.8 - $3.96 $42,904 - $60,679	-15,323 Reduced 73.22%	5,605 $20,000
Q4 2021 Feb 10, 2022	SELL	$3.63 - $6.13 $342,962 - $579,162	-94,480 Reduced 81.87%	20,928 $82,000
Q3 2021 Nov 10, 2021	BUY	$5.5 - $7.41 $634,744 - $855,173	115,408 New	115,408 $761,000

Others Institutions Holding LAB

# of Institutions

143

Shares Held

274M

Call Options Held

6.7K

Put Options Held

48.7K

View Full List

About STANDARD BIOTOOLS INC.

Ticker LAB
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 78,654,800
Market Cap $89.7M
Description
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar ...

More about LAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account